Physician profile
Stephen Ake
NPI 1659657948
$915.71
in general payments reported to CMS, 2019-2025
20 companies · $17.74 in 2025
The $17.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.77 · 2021: $29.99 · 2022: $18.26 · 2023: $265 · 2024: $569 · 2025: $17.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $195.82 | 2023-2024 | Accrufer |
| Glaxosmithkline, LLC. | $90.78 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Inspire Medical Systems, INC. | $77.56 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $69.63 | 2021-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $68.33 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.99 | 2024 | Jardiance |
| Lilly USA, LLC | $51.33 | 2023-2024 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.91 | 2023-2024 | Xifaxan, Trulance, Cycloset |
| Exact Sciences Corporation | $30.12 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $28.55 | 2023-2024 | Quviviq |
| Medtronic, INC. | $27.29 | 2024 | Minimed 780g |
| Pfizer INC. | $26.66 | 2024 | |
| Merck Sharp & Dohme LLC | $23.20 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $21.62 | 2024 | Veozah |
| Amgen INC. | $19.96 | 2024 | Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $18.79 | 2023 | Heplisav-B |
| Abbott Laboratories | $18.26 | 2022 | |
| Genentech USA, INC. | $18.03 | 2021 | |
| Amarin Pharma, INC. | $15.77 | 2019 | |
| Sanofi Pasteur INC. | $15.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.